INTRODUCTION
============

Schizophrenia is a chronic debilitating psychiatric disorder. Despite many studies examining the etiology of schizophrenia the exact cause remains unknown. The evidence of infection as a cause of schizophrenia was supported by the brain histopathological changes found in patients with schizophrenia \[[@b1-kjp-53-1-29]-[@b3-kjp-53-1-29]\]. Studies had documented that astrocytes and neurons of the brain could be infected by *Toxoplasma gondii* (*Tg*). The infection then stimulated the production of a variety of cytokines by microglia, astrocytes, and neurons which in turn initiated inflammatory responses \[[@b4-kjp-53-1-29],[@b5-kjp-53-1-29]\]. The parasites formed cysts within the brain and produce an enzyme called tyrosine hydroxylase, which was needed for dopamine production \[[@b4-kjp-53-1-29]-[@b6-kjp-53-1-29]\]. Dopamine's role in schizophrenia is well documented. The tyrosine hydroxylase converted L-Dopa to dopamine. An excess of dopamine as a pathological basis for schizophrenia was substantiated by the fact that antipsychotic drugs decreased the brain dopamine thus reducing the symptoms of schizophrenia \[[@b7-kjp-53-1-29]-[@b9-kjp-53-1-29]\]. In addition, antipsychotics inhibited the replication of *Tg* \[[@b10-kjp-53-1-29],[@b11-kjp-53-1-29]\]. *Tg* infection of the brain increased levels of dopamine \[[@b12-kjp-53-1-29]-[@b16-kjp-53-1-29]\] and caused psychotic symptoms resembling schizophrenia \[[@b17-kjp-53-1-29],[@b18-kjp-53-1-29]\]. Artemether, an antiparasitic agent, significantly reduced negative symptoms of schizophrenia compared to controls \[[@b19-kjp-53-1-29]\].

Almost all previous studies concerning the association of *Tg* infection and schizophrenia were based on indirect measurement by examining antibodies, i.e., IgG and IgM \[[@b20-kjp-53-1-29]-[@b23-kjp-53-1-29]\], and the results were inconclusive \[[@b24-kjp-53-1-29]\]. Whilst some studies \[[@b24-kjp-53-1-29]-[@b27-kjp-53-1-29]\] demonstrated positive associations, others found the contrary \[[@b28-kjp-53-1-29],[@b29-kjp-53-1-29]\]. The purpose of this study was, therefore, to specifically appraise the relationship between schizophrenia and *Tg* infection using both indirect and direct methods by measuring *Tg* antibodies and DNA, respectively, in comparison to the controls. The findings would further help in understanding the etiology of schizophrenia which in turn would contribute to the preventive measures and development of a new pharmacological treatment approach for schizophrenia.

MATERIALS AND METHODS
=====================

Subjects
--------

This was a cross-sectional case control study examining the serofrequency and serointensity of *Tg* among patients with schizophrenia and controls, assessed through indirect and direct methods by measuring *Tg* IgG and IgM antibodies and DNA, respectively. A total of 101 patients with schizophrenia and healthy individuals as controls (n=55) attending Sungai Buloh Hospital, Selangor, Malaysia and University Malaya Medical Center (UMMC) who fulfilled the criteria were recruited in this study. Controls were recruited from all consecutive patients attending medical out-patient clinic comprised of patients with chronic hypertension and diabetic with no psychiatry illness. The diagnosis of schizophrenia was made by psychiatrists using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), American Psychiatric Association, 1994 \[[@b30-kjp-53-1-29]\]. The ethical approvals were obtained from Universiti Teknologi Mara (UiTM), \[UiTM 600-RMI(5/1/6)\], UMMC (UMMC 932.46), and National Medical Register Research (NMRR), (NMRR-10-852-6764) Ethics Committees. The purpose of the study was explained and a written consent was obtained from patients or the legal guardians. Their demographic data were also recorded.

Detection of *Tg* IgG, IgM, and DNA
-----------------------------------

Five ml of blood samples were collected, centrifuged at 1,500 rpm in 15 min at 4˚C, and stored at -20˚C. *Tg* IgG and IgM antibodies and DNA were measured using ELISA (IBL Company, Hamburg, Germany) and quantitative real-time PCR (qPCR), respectively. The extraction of DNA was performed using QIAamp^®^ Blood Mini Kit from Qiagen (Hilden, Germany). The tests were all conducted according to the instructions from the manufacturers. *Tg* IgG and IgM antibodies were measured from serum using the commercial ELISA kit according to the manufacturer's instructions. Samples absorbance were read using the microtiter plate reader at absorbance of 450/620 nm. Patients and control sera were obtained from blood at the same time as the interviews. Each sample was done triplicate to ensure the reliability of results and the experiments were done in sterile conditions. Positive results were recorded when the quantity of antibodies of IgG and IgM were more than 35 IU/ml and 11 IU/ml, respectively.

The forward primer for qPCR was (5´-TCCCCTCTGCTGGCGAAAAGT-3´), whilst (5´-AGCGTTCGTGGTCAACTATCGATTG-3´) was the reverse primer and (5´6FAM-TCTGTGCAACTTTGGTGTATTCGCA-BHQ1-3´) was the probe primer. A 8-μl of template DNA was added to the final volume of 25 μl reaction mixture, which consists of 6.5 μl of iTAQ Universal Probes Supermix, 0.25 μl (20 μM) Taqman probe, 0.625 μl (20 μM) of each primer, and distilled water. The amplification processes were performed using the Bio-Rad CFX96 machine (Bio-Rad, Hercules, California, USA). The PCR cycling condition was done at 95˚C for 10 min (initial denaturation), followed by 40 cycles at 95˚C for 15 sec (further denaturation), 60˚C for 1 min (annealing), they were then hold for 10˚C. Several sets of PCR amplification using 6 different concentrations of positive samples were performed to calibrate the real-time PCR condition in order to obtain a standard curve with R^2^ more than 85% and Cq standard deviation of less than 0.5. The quantity of the gene was determined using the cycle threshold value (C~T~ value) by BIORAD CFX Software Version 2.1 (Bio-Rad).

Statistical analysis
--------------------

The results were analyzed using Statistical Package for Social Sciences (SPSS) version 20 (Chicago, Illinois, USA). The serofrequency of *Tg* IgG and IgM antibodies were calculated by descriptive statistics (frequencies), and the differences between the groups were calculated using the chi-square or Fisher's exact test. The differences in medians were compared using the Mann-Whitney U test. The odd ratio (OR) and its 95% Confident Interval (CI) were used to estimate the strength of the association between *Tg* infection and schizophrenia.

RESULTS
=======

The demographic profiles of the patients with schizopherenia (n=101) and controls (n=55) were comparable in terms of age, gender, and ethnicity ([Table 1](#t1-kjp-53-1-29){ref-type="table"}). The mean ages of controls and patients with schizophrenia were 45.3±14.5 years (range; 21-63 years) and 41.1±10.9 years (18-65 years), respectively. The duration of illness for patients with schizophrenia was 6.5±4.9 years (1.0-13.5 years). Unemployment was significantly (*P*=0.01) higher among patients with schizophrenia (63.2%) compared to controls (50.9%). The majority of patients with schizophrenia were single (56.1%) compared to controls (27.3%) (*P*=0.0005). Patients with schizophrenia had a lower level of education (*P*=0.001) and income (*P*=0.0005) than controls. The seropositivity and seronegativity of *Tg* IgG, IgM, and DNA are shown in [Table 2](#t2-kjp-53-1-29){ref-type="table"}.

*Tg* IgG antibody was positive in 52 (51.5%) and 10 (18.2%) of patients with schizophrenia and controls, respectively (*P*=0.0005, OD=4.78, 95% CI=2.17-10.51). Meanwhile, the IgM antibody was found in 4 (7.7%) of patients with schizophrenia and none (0%) in controls (OR=3.97, P=0.34, CI= 0.20-78.25). DNA for *Tg* was positive in 33 (32.67%) of patients with schizophrenia and 2 (3.64%) of controls (*P*= 0.0005, OD=12.86, CI=2.95-56.03). [Table 3](#t3-kjp-53-1-29){ref-type="table"} shows the serointensity of *Tg* IgG, IgM, and DNA among patients and controls. The levels of *Tg* IgG antibody were not significantly different (*P*\>0.005) in patients with schizophrenia (214.6±163.1 IU/ml) compared to controls (138.4±83.6 IU/ml, *P*=0.06). There was no significant difference between *Tg* DNA levels of patients with schizophrenia (0.09 ng/ml) vs controls (0.03± 0.65 ng/ml) (*P*=0.23). [Figs. 1](#f1-kjp-53-1-29){ref-type="fig"} and [2](#f2-kjp-53-1-29){ref-type="fig"} show the data of qPCR in controls and patients with schizophrenia, respectively.

DISCUSSION
==========

Our findings showed that there were significant differences between seropositivity of *Tg* IgG antibody and DNA among patients with schizophrenia compared to controls, suggesting the important role of *Tg* infection in schizophrenia. These results were consistent with previous studies which found a positive association between *Tg* IgG antibody and schizophrenia \[[@b20-kjp-53-1-29],[@b23-kjp-53-1-29]-[@b25-kjp-53-1-29],[@b31-kjp-53-1-29],[@b32-kjp-53-1-29]\]. The majority of previous studies determined the presence of *Tg* infection through an indirect method (using ELISA) by measuring *Tg* IgG and IgM antibodies. There was, however, no study using real-time qPCR to examine the association between schizophrenia and *Tg* infection. The strength of this study was the use of both indirect and direct methods for examining the presence of *Tg* antibodies and DNA, respectively.

The positivity of *Tg* DNA was significantly higher in patients with schizophrenia than controls with the OR of 12.9. The average OR of previous studies (based on positivity of antibodies) over 5 decades in 17 countries demonstrated an average OR of 2.54 \[[@b20-kjp-53-1-29],[@b33-kjp-53-1-29]\]. In our study, the OR of having schizophrenia among those with positive *Tg* DNA (OR=12.9) was much higher than those with positive *Tg* IgG antibody (OR=4.8). The high OR of *Tg* infection in schizophrenia measured by *Tg* DNA in our study indicated that the risk of having schizophrenia among those infected with *Tg* was much higher than previously considered, signifying that there was a strong relationship between *Tg* and schizophrenia. The finding also suggested that acute infections of *Tg* could specifically play an important role in schizophrenia. The detection of *Tg* infection through direct measurement of DNA was more reliable because it signified the active *Tg* infection, whereas the seropositivity of *Tg* IgG would merely indicate the presence of antibodies (as a result of exposure to *Tg*).

There was no significant difference between *Tg* IgM antibody in patients with schizophrenia and controls. This finding was consistent with previous studies \[[@b34-kjp-53-1-29]-[@b36-kjp-53-1-29]\]. This could probably be due to the fact that patients often present late to the hospital. The presence of IgM antibodies is time-dependent, and IgM is secreted immediately following infection and would remain positive for 1 or 2 weeks indicating a recent infection. This issue was addressed in this study by examining *Tg* DNA which reflected the presence of an acute *Tg* infection.

Although there was significant difference in the seropositivity of *Tg* IgG and *Tg* DNA between the 2 groups, however, there was no significant difference between the serointensity of *Tg* IgG antibody and DNA between schizophrenia patients and controls. These could possibly be due to the effects of antipsychotic medications which caused the reduction in the level of *Tg* IgG antibody and DNA by inhibiting the replication of *Tg* \[[@b10-kjp-53-1-29],[@b11-kjp-53-1-29]\]. The antibody levels for untreated patients with schizophrenia were found to be the highest followed by the treated and controls \[[@b34-kjp-53-1-29]\]. The effects of antipsychotic drugs on *Tg* IgG and DNA levels could be addressed by examining patients with schizophrenia at acute stage, those with the first episode or drug naïve. Secondly, the level of IgG was related to timing of infection and individual body response.

Although our study had strongly demonstrated the association between *Tg* infection and schizophrenia, a more comprehensive research is required to consolidate these findings. A cohort study involving drug naïve schizophrenia patients would be critical in demonstrating the specificity of the association and would further enlighten the etiological role of *Tg* in schizophrenia. The clinical factors such as the stages of illness, presentation of symptom, sub-types of schizophrenia as well as treated and non-treated cases should also be considered and addressed.

There were some limitations in this study namely it was a cross-sectional study and there was no comparison to other types of psychosis. A prospective case control study involving a larger sample would be of great help in examining this association. Nevertheless, our study showed that there was a highly significant association between *Tg* infection and schizophrenia. The strength of the association between *Tg* infection and schizophrenia was much higher than previously considered. Identifying *Tg* roles in schizophrenia would help in the preventive measures and pharmacological approaches in the treatment of schizophrenia.
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###### 

Demographic profiles of patients with schizophrenia and control

  Demographic profile                                          Control (n=55)       Schizophrenia (n=101)       Chi square value       *P*-value                      
  ------------------------- ---------------------------------- -------------------- --------------------------- ---------------------- --------------- ------ ------- --------
  Age                       Mean (SD)                          45.3 ± 14.5          41.1 ± 10.9                 1.86                   0.07                           
                            Range                              21-63 years                                                             18-65 years                    
  Duration of Illness       Mean (SD)                                                                                                  6.5 ± 4.9                      
                            Range                                                                                                      1-13.5 years                   
                                                                                                                                                                      
                                                               **Control (n=55)**   **Schizophrenia (n=101)**   **Chi square value**   ***P*-value**                  
                                                               **n**                **(%)**                     **n**                  **(%)**                        
                                                                                                                                                                      
  Occupation                Employed                           27                                               49.1                   28              36.8   7.12    0.01
                            Unemployed                         28                                               50.9                   73              63.2           
  Gender                    Male                               24                   43.6                                                58             52.6   2.72    0.10
                            Female                             31                   56.4                                                43             47.4           
  Ethnicity                 Malay                              22                   40.0                                                45             40.4   0.33    0.85
                            Chinese                            20                   36.4                                                35             42.1           
                            Indian                             13                   23.6                                                21             17.5           
  Marital status            Married                            38                   69.1                                                30             35.1   22.47   0.0005
                            Single/Widowed/divorced            17                   27.3                                                71             56.1           
  Education level           Upper Secondary School and above   39                   70.9                                                44             43.9   10.69   0.001
                            Lower Secondary School and below   16                   29.1                                                57             56.1           
  Family Income per month   \< RM2000                          25                                               25.5                   92              64.9   39.55   0.0005
                            RM2000 and above                   30                                               74.5                   9               35.1           

RM, Ringgit Malaysia (Malaysian Currency).

###### 

Seropositivity and seronegativity of *T. gondii* IgG and IgM antibodies and DNA among patients with schizophrenia and control

  Immunoglobulin and DNA   Control (n=55)   Schizophrenia (n=101)   *P*-value   Chi-square   OR (95% CI)
  ------------------------ ---------------- ----------------------- ----------- ------------ --------------------
  IgG positive             10               52                      0.0005      16.43        4.78 (2.17-10.51)
  IgG negative             45               49                                               
  IgM positive             0                4                       0.34        0.93         3.97 (0.20-78.25)
  IgM negative             55               97                                               
  DNA positive             2                33                      0.0005      17.25        12.86 (2.95-56.03)
  DNA negative             53               68                                               

###### 

Serointensity of *Toxoplasma gondii* IgG and IgM antibodies and DNA among patients with schizophrenia and control

  Serointensity of antibodies/DNA   Control (n=55)   Schizophrenia patient (n=101)   *P*-value   Test value                             
  --------------------------------- ---------------- ------------------------------- ----------- ------------ -------- -------- ------- -------
  IgG IU/ml                         138.38           214.58                          83.64       214.58       441.53   163.07   0.063   1.86
  IgM IU/ml                         NA               NA                              NA          42.03        71.43    65.18    NA      NA
  DNA ng/ml                         0.09             0.13                            NA          0.30         21.68    0.65     0.227   1.208
